DELCATH SYSTEMS, INC.
DCTHNasdaq
$12.81
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +13.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$461.4M
Enterprise Value
$372.1M
P/E
1281.0
P/S
5.1
P/B
4.1
EV/EBITDA
—
PEG
—
FCF Yield
4.2%
Dividend Yield
—
Revenue (TTM)
$90.4M
Net Income (TTM)
$561,000.00
Free Cash Flow (TTM)
$19.2M
Gross Margin
86.0%
Operating Margin
-1.8%
Net Margin
0.6%
ROE
0.5%
ROIC
-3.5%
Debt / Equity
—
Net Cash
$89.3M
Return 1Y
+13.2%
Company profile
Delcath Systems, Inc. focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver.
- CEO
- Gerard J. Michel
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 60
- Headquarters
- New York
- Website
- delcath.com
Management & directors
- Pennell SandraChief Financial Officer
- Michel Gerard JCHIEF EXECUTIVE OFFICER
Roles derived from SEC Form 4 filings.
Earnings
DCTH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$25.0M↑ +26.3%
Diluted EPS-$0.03↓ -200.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $3.6M | $2.7M | $2.1M | $37.2M | $85.2M |
| Gross profit | $1.0M | $2.9M | $2.0M | $1.4M | $31.0M | $73.4M |
| Operating income | -$21.3M | -$24.5M | -$33.9M | -$38.2M | -$12.4M | $660,000.00 |
| Net income | -$24.2M | -$25.6M | -$36.5M | -$47.7M | -$26.4M | $2.7M |
| Diluted EPS | -$8.35 | -$3.59 | -$4.12 | -$2.94 | -$0.93 | $0.07 |
| Operating cash flow | -$22.9M | -$22.6M | -$24.9M | -$31.3M | -$18.7M | $22.5M |
| Free cash flow | -$23.6M | -$22.7M | -$25.2M | -$31.3M | -$19.2M | $21.0M |
| Gross margin | — | 81.1% | 74.8% | 69.2% | 83.4% | 86.2% |
| Operating margin | — | -690.0% | -1245.1% | -1849.0% | -33.4% | 0.8% |
| Net margin | — | -721.5% | -1342.7% | -2308.9% | -70.9% | 3.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $11.2M | $15.1M | $19.8M | $24.2M | $20.6M | $20.7M | $25.0M |
| Gross profit | $6.2M | $9.6M | $13.0M | $16.9M | $20.8M | $17.9M | $17.7M | $21.3M |
| Operating income | -$3.9M | -$1.3M | $3.0M | $642,000.00 | $2.6M | -$388,000.00 | -$2.2M | -$1.6M |
| Net income | -$13.7M | $1.9M | -$3.4M | $1.1M | $2.7M | $830,000.00 | -$1.9M | -$1.1M |
| Diluted EPS | -$0.48 | $0.06 | -$0.06 | $0.03 | $0.07 | $0.02 | -$0.05 | -$0.03 |
| Operating cash flow | -$4.5M | -$3.6M | -$1.0M | $2.2M | $7.3M | $4.8M | $8.2M | $857,000.00 |
| Free cash flow | -$4.6M | -$3.9M | -$1.2M | $2.1M | $6.9M | $4.3M | $7.7M | $287,000.00 |
| Gross margin | 80.4% | 85.4% | 85.9% | 85.6% | 86.3% | 87.2% | 85.5% | 85.1% |
| Operating margin | -50.4% | -11.2% | 20.1% | 3.2% | 10.7% | -1.9% | -10.5% | -6.5% |
| Net margin | -176.9% | 16.6% | -22.5% | 5.4% | 11.2% | 4.0% | -9.1% | -4.3% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-06 | Pennell Sandra· Chief Financial Officer | Buy | 5,533 | $9.04 | $50,018.32 | filing |
| 2026-03-02 | MICHEL GERARD J· CHIEF EXECUTIVE OFFICER | Buy | 11,200 | $8.96 | $100,309.44 | filing |
| 2025-11-21 | Sylvester John Richard | Buy | 4,386 | $8.89 | $38,991.54 | filing |
| 2025-11-11 | MICHEL GERARD J· CHIEF EXECUTIVE OFFICER | Buy | 11,500 | $8.53 | $98,049.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.